Passage Bio (PASG) Insider LP Buys $206K of Stock
Lynx1 Capital Management LP acquired 50,055 shares of PASG, enhancing its position.
Reviewed by automated data checks against the source filing. How we make and check alerts
Lynx1 Capital Management LP bought 50,055 shares of Passage Bio, Inc. ($PASG) at an average price of $4.12, worth about $206,226.60, on June 25, 2026. The trade was reported to the SEC in a Form 4 filing.
Since the trade, $PASG is up 8.1% after 1 week, up 6.7% after 1 month and down 19.2% to date (from the $4.33 close on Jun 25, 2026).
PASG
Passage Bio, Inc.
Key Points
- Lynx1 Capital Management LP purchased 50,055 shares of PASG on June 25, 2026, for $206,226.60.
- PASG shares traded near $4.85 on Tuesday, with a recent analyst downgrade to 'hold'.
- Renaissance Technologies increased its PASG shares by 24,523, while Yiheng Capital Management boosted its holding by 151%.
Get $PASG trade alerts by text
We text you when insiders, Congress or big funds trade $PASG. Free.
Not investment advice. EarningsIQ is not a registered investment adviser, and this automated Passage Bio, Inc. alert may contain errors. Disclosures
Lynx1 Capital Management LP made a substantial move by purchasing 50,055 shares of PASG on June 25, 2026. This transaction was valued at approximately $206,226.60 at an average price of $4.12 per share, signaling a notable increase in their stake.
Other Institutional Activity in PASG
Other institutional investors have also been active in PASG. Renaissance Technologies LLC increased its holdings by 24,523 shares, bringing its total to 133,612 shares valued at about $1,048,854, marking a 22.5% increase. Yiheng Capital Management, L.P. significantly boosted its position by 51,796 shares, ending with 86,097 shares worth approximately $675,861, reflecting a 151% increase. Meanwhile, Vanguard Capital Management LLC opened a new position with 113,964 shares valued at roughly $894,617.
Passage Bio, Inc. Stock Up 2.1%
Shares of PASG traded near $4.85 on Tuesday. The stock has been under scrutiny with recent analyst activity, including a downgrade from Chardan Capital to a 'hold' rating with a price target of $7.0. The stock's movements are closely watched as it navigates market conditions.
Insider Buying and Selling at Passage Bio, Inc.
Lynx1 Capital Management LP's recent acquisition of 50,055 shares at $4.12 per share adds to the series of insider activities. On May 19, 2026, other insiders like Thomas Richard Kassberg, Dolan Sondhi, Sandip Kapadia, Derrell Porter, and Maxine Gowen each bought 10,539 shares.
Analysts Set New Price Targets
On April 21, 2026, Chardan Capital downgraded PASG to a 'hold' with a $7.0 price target, while Oppenheimer maintained a 'buy' rating with a $15.0 target. Wedbush also downgraded the stock to 'hold' with an $8.0 target. The consensus among analysts remains varied, reflecting differing perspectives on the company's potential.
Bottom Line
Lynx1 Capital's recent purchase of PASG shares indicates a continued interest in the company. While insider activities and analyst ratings vary, these moves provide investors with insights into institutional and expert sentiments. Remember, 13F filings and insider transactions are historical and may not reflect current positions.
Related Filing Alerts
Source: Lynx1 Capital Management LP's Form 4 filing on $PASG (Jun 25, 2026). Find the original filing: PASG Form 4 filings on SEC EDGAR. Written by software, not financial advice. How we make alerts